We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Emergent BioSolutions announced it has submitted an investigational new drug application to the FDA for its anthrax immune globulin (AIG) product candidate.
Aeolus Pharmaceuticals has announced the successful completion of the analysis of results from its Phase I multiple-dose study of AEOL 10150 (Study 102).
Alexza Pharmaceuticals announced positive top-line results from its 400-patient Phase IIb clinical trial of AZ-001 (Staccato prochlorperazine) in patients with migraine headache.
Scios, a wholly owned subsidiary of Johnson & Johnson (J&J), announced that an exploratory 920-patient, Phase II study of Natrecor (nesiritide) showed a neutral effect on the primary endpoint, a composite of death and cardiorenal hospitalization at 12 weeks, but provides important renal and mortality safety data on Natrecor in patients with advanced chronic decompensated heart failure (CDHF) receiving serial outpatient infusions.
Schering-Plough presented results of a Phase II trial of its novel oral thrombin receptor antagonist (TRA), SCH 530348, at the American College of Cardiology's meeting in New Orleans.
Hana Biosciences announced it has decided to stop development of its current Zensana formulation and withdraw the new drug application (NDA) it submitted to the FDA in June 2006, without prejudice.
UCB announced it has decided to initiate an additional short-term clinical study of Cimzia (certolizumab pegol) to confirm the induction of clinical response in moderate to severe active Crohn's disease.